Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
40 Results for "
CYP17A1
" in MedChemExpress (MCE) Product Catalog:
Products (40)
40 Results for "CYP17A1" in MCE Product Catalog:
24
Target:
Research Areas:
Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
24
Target:
Research Areas:
Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
1
1 Cited Publications
Cat. No.: HY-B0105B
CAS No.: 142128-57-2
Synonyms: (-)-Ketoconazole; (-)-Ketoconazol; (-)-R 41400
Target:
Research Areas:
Levoketoconazole ((-)-Ketoconazole) is the 2S,4R enantiomer derived from racemic Ketoconazole (HY-B0105). Levoketoconazole is a potent and orally active cortisol synthesis inhibitor. Levoketoconazole inhibits key steps in cortisol and testosterone synthesis by inhibiting CYP11B1, CYP11A1, and CYP17A1. Levoketoconazole can be used for research on endogenous Cushing’s syndrome .
Cat. No.: HY-70013S
CAS No.: 2122245-62-7
Synonyms: CB-7598-d4
Synonyms: Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite
Target:
Research Areas:
D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor.
Cat. No.: HY-W073128
CAS No.: 376-06-7
Synonyms: PFTeDA
Research Areas:
Perfluorotetradecanoic acid (PFTeDA) is an orally active perfluoroalkyl substance. Perfluorotetradecanoic acid directly binds to the ligand-binding domain of purified hPPARγ, with a Kd value of 157.8 μM. Perfluorotetradecanoic acid significantly reduces the activity of the SIRT1/PGC1α and AMPK signaling pathways while stimulating the activity of the AKT1/mTOR signaling pathway. Perfluorotetradecanoic acid significantly upregulates the expression of corticosterone biosynthesis genes. Perfluorotetradecanoic acid increases ROS levels and promotes Apoptosis. Perfluorotetradecanoic acid impairs Leydig cell function and male reproductive endocrine function in adult male rats .
Cat. No.: HY-75054R
CAS No.: 154229-18-2
Synonyms: CB7630 (Standard)
Target:
Research Areas:
Abiraterone acetate (Standard) is the analytical standard of Abiraterone acetate. This product is intended for research and analytical applications. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
Cat. No.: HY-W741510
CAS No.: 1882-82-2
Synonyms: 21-Desoxycortisone; NSC 38722
Target:
Research Areas:
21-Deoxy Cortisone (21-Desoxycortisone; NSC 38722) is a corticosteroid metabolite of 11-ketoprogesterone. It is formed from 11-ketoprogesterone by the cytochrome P450 (CYP) isozyme CYP17A1, but can also be produced by oxidation of 21-deoxycortisone (HY-113405) by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). Congenital adrenal hyperplasia is an inborn error of metabolism characterized by a deficiency of 21-hydroxylase, and 21-Deoxy Cortisone levels are elevated in patients with congenital adrenal hyperplasia.
Target:
Research Areas:
Abiraterone sulfate is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
Synonyms: 3β-OH-5α-Abi
Target:
Research Areas:
Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.
Target:
Research Areas:
SU 10603 is a specific inhibitor of P45017α (P450c17; CYP17A1) .
Cat. No.: HY-RS03437
Target:
Research Areas:
CYP17A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP17A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-137193
CAS No.: 219843-75-1
Target:
Research Areas:
5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .
Cat. No.: HY-RS17785
Target:
Research Areas:
Cyp17a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cyp17a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS24252
Target:
Research Areas:
Cyp17a1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cyp17a1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-175972
Target:
Research Areas:
CAI/II-IN-12 is a potent and hCAI (IC50 = 7.12 μM, Ki = 9.26 μM) and hCAII (IC50 = 10.62 μM, Ki = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma .
Cat. No.: HY-172173
Target:
Research Areas:
CYP17A1-IN-1 (Compound 14) is the inhibitor for CYP17A1 with an IC50 of 26 nM. CYP17A1-IN-1 exhibits cytotoxicity in androgen-sensitive prostate cancer cell LNCaP, inhibits the migration of cell DU-145 .
Cat. No.: HY-163359
CAS No.: 3047489-22-2
Target:
Research Areas:
CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC50 of 0.284μM and 0.6015 μM,respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity .
Cat. No.: HY-111421
CAS No.: 1642818-64-1
Target:
Research Areas:
ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC50s of 80 nM and 22 nM, respectively.
Cat. No.: HY-181045
Target:
Research Areas:
CYP17A1-IN-2 is a potent inhibitor of CYP17A1. CYP17A1-IN-2 exhibits anti-proliferative activity against prostate cancer cells. CYP17A1-IN-2 can be used in research related to castration-resistant prostate cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
